303 Drug Tition Fierce Competition
Medical Network September 9th News On September 6, the official website of China Pharmaceutical Association released the "Announcement on the Release of the Fifth Batch of Over-Repeated Drugs", with 303 drugs on the list of over-repeated varieties.
According to the announcement, the State Food and Drug Administration commissioned the Chinese Pharmaceutical Association to study and publish information on over-repeated drug tips.
According to the screening conditions of over-repeated generic varieties, China Pharmaceuticals will monitor and analyze the sales of approved drugs in 2016-2018, and form the fifth batch of over-repeated drug tips information catalogue. This catalogue consisted of 303 over-repeated varieties, involving 14 major categories and 60 sub-categories of clinical pharmacology and therapeutic classification, and an over-repeated catalogue published in the "Announcement on the Release of the Fourth Batch of Over-Repeated Drug Tips". In comparison, 7 varieties were transferred and 1 variety was transferred.
The Chinese Pharmaceutical Association reminds relevant pharmaceutical manufacturers and R&D institutions to fully understand the market supply and demand situation, scientifically evaluate the risk of drug research and development, and carefully make investment management decisions. Local regulatory authorities should strengthen their guidance to enterprises, take the initiative to do a good job of propaganda work on the over-repeated drug varieties that have been announced, and guide enterprises to rational research and development and declaration.
Since September 2014, the former State Food and Drug Administration announced the “First Batch of Over-repeated Drug Varieties”, which is now the fifth batch. From the published catalogue, we can find that over-repeated drugs have been produced or are being declared for production, and market demand is saturated or nearly saturated
.
For example, metronidazole, the number of approvals has reached 1,171, and the number of approved enterprises has reached 804. The CMEI monitoring shows that the 10 products with the highest sales in the market have occupied 73.15% of the market share;
There are 375 approvals for pediatric aminophenol Huangnamin. The number of approved enterprises has reached 351. The CMEI monitoring shows that the 10 products with the highest sales in this market have occupied 96.96% of the market share;
Aspirin, the number of approvals has reached 577, and the number of approved enterprises has reached 347. CMEI monitoring shows that the 10 products with the highest sales in this category have occupied 99.26% of the market share.
There are many varieties, the current market is highly saturated, and it is not appropriate to continue the new declaration. From this aspect, we can also see that many varieties, especially generic drugs, are currently in a highly competitive situation.
Under the influence of a series of policies such as two-vote system, quantity procurement, and GPO, some products that did not have a foothold in the market and have a certain share in the early stage are likely to be gradually eliminated by the market and eventually embarked on the road of cancellation of approval.
